View the original article here
This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.
View the original article here
View the original article here
Novartis Study Shows Omalizumab Effective In Severe Form Of Chronic Skin ... NASDAQ (RTTNews.com) - Novartis AG ( NVS ) Saturday announced new results from the Phase III ASTERIA I study showing omalizumab was effective and safe in the treatment of chronic spontaneous urticaria or CSU, a chronic and debilitating form of hives. Novartis says drug reduces itch of severe chronic hives Novartis announces positive results from final Phase III omalizumab registration ... |